Evidence map›Paper›PMID 42859764›Full record

ArticleInternational journal of particle therapy2026

Clinical Outcomes of Carbon-Ion Radiotherapy for Unresectable Radiation-Induced Secondary Sarcoma.

Kazuhiko Hayashi, Osamu Suzuki, Koji Ichise, Hirofumi Uchida, Fumiko Nagano, Azusa Hasegawa, Shinichi Shimizu, Jiro Fujimoto, Kazuhiko Ogawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazuhiko HayashiDepartment of Radiology, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Osamu SuzukiDepartment of Radiology, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Koji IchiseDepartment of Radiology, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Hirofumi UchidaDepartment of Radiology, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Fumiko NaganoDepartment of Radiology, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Azusa HasegawaDepartment of Radiology, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Shinichi ShimizuDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Jiro FujimotoDepartment of Radiology, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Kazuhiko OgawaDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: While carbon-ion radiotherapy (CIRT) is a promising treatment option for unresectable sarcomas, its efficacy and safety for radiation-induced secondary sarcomas (RIS) remains unclear owing to limited evidence. This study aimed to evaluate the feasibility and safety of CIRT for RIS at our center. Patients and Methods: Data concerning 8 patients who had undergone CIRT for RIS between December 2018 and December 2024 were retrospectively analyzed. Toxicities were evaluated using Common Terminology Criteria for Adverse Events, version 5.0. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were determined using the Kaplan-Meier method. Results: The median follow-up period was 18.5 months (range, 3.1-32.6 months). The primary malignancies included cervical cancer ( Conclusion: Our findings suggest that CIRT for unresectable RIS is feasible with acceptable short-term toxicities.

Indexed as

Bone and soft tissue tumorCarbon-ion radiotherapyFeasibilityRadiation-induced sarcomaToxicities

Identifiers

PMID42859764
PMCPMC13653467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.